About Flash Therapeutics
Flash Therapeutics is a Healthcare company based in Toulouse (France) founded in 2005. Gene-based therapeutics are developed for multiple disorders. Flash Therapeutics has raised $11.54 million across 6 funding rounds from investors including TechLife Capital, Elaia and Galia Gestion. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.
Company details
The company was founded in 2005 and is based in Toulouse, France. Operations focus on the biotechnology sector, where gene and cell-based therapies are developed for conditions such as IPEX syndrome and lymphedema. Technologies employed include a lentiviral platform, transient RNA delivery, CAR-T cancer immunotherapy, and gene-editing tools. These efforts target therapeutic solutions for various disorders.
- Headquarters Toulouse, France
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website flashtherapeutics.com
- Social LinkedIn X
- Total Equity Funding$11.54M (USD)
in 6 rounds
- Latest Funding Round$4.72M (USD), Series A
Jul 2021
- InvestorsTechLife Capital
& 9 more
Funding Insights of Flash Therapeutics
Flash Therapeutics has successfully raised a total of $11.54M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $4.72 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.54M
- Total Rounds 6
- Last Round Series A — $4.72M
- First Round $1.35M
(May 2010)
- Investors Count 10
All 6 funding rounds of Flash Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $4.72M | Series A | – | – | |
| May 2018 | $3.9M | Series A | – | – | |
| Aug 2017 | $59,656 | Grant | – | – | |
| Jun 2017 | Series A | – | Viva Ventures Biotech Fund | – | |
| Apr 2012 | $1.57M | Series A | – | Fa Diese, FJ INVESTISSEMENT | – |
| May 2010 | $1.35M | Series A | – | Fa Diese, FJ INVESTISSEMENT | – |
10 investors in total: 8 institutional and 2 angel.
Investors in Flash Therapeutics
Flash Therapeutics has secured backing from 10 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include TechLife Capital, Elaia and Galia Gestion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| techlifecapital.com | ||||
Venture capital firm focused on early-stage investments | elaia.com | Paris, France | ||
Galia Gestion is engaged in private equity investments in southwestern France. | galia-gestion.com | Bordeaux, France | ||
Venture capital investments are managed by Auriga Partners in France. | 1998 | aurigapartners.com | Paris, France | |
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
| vivaventuresbiotech.com | ||||
| fadiese.fr | ||||
A real estate fund specializing in multiple investment strategies for institutional clients. | fj-investissement.fr | Besancon, France | ||
JA Jean-Pierre Arnaud | unknown_266170804e6449a39 | |||
AS Alain Sainsot | unknown_e3a33671c7db48fbb |
Investor details for Flash Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Flash Therapeutics
3 dated milestones of Flash Therapeutics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Flash Therapeutics is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series A, of $4.7M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Flash Therapeutics
Complete news archive for Flash Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Flash Therapeutics
Flash Therapeutics was founded in 2005 and raised its 1st funding round 5 years after it was founded.
Flash Therapeutics is headquartered in Toulouse, France. It is registered at Toulouse, Occitanie, France.
Flash Therapeutics is a funded company, having raised a total of $11.54M across 6 funding rounds to date. The company's 1st funding round was a Series A of $1.35M, raised on May 2010.
The company was founded in 2005 and is based in Toulouse, France. Operations focus on the biotechnology sector, where gene and cell-based therapies are developed for conditions such as IPEX syndrome and lymphedema. Technologies employed include a lentiviral platform, transient RNA delivery, CAR-T cancer immunotherapy, and gene-editing tools. These efforts target therapeutic solutions for various disorders.
Flash Therapeutics has 10 investors. Key investors include TechLife Capital, Elaia, Galia Gestion, Jean-Pierre Arnaud, and Alain Sainsot.